New combo targets genetic weakness in tough pancreatic cancer

NCT ID NCT06790602

Recruiting now Disease control Sponsor: University of California, San Diego Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether adding the immunotherapy drug cemiplimab to standard chemotherapy gemcitabine can help people with a certain genetic type of advanced pancreatic cancer live longer. The study enrolls 43 adults whose cancer has spread and who have already tried one prior treatment. Researchers are looking at overall survival as the main goal.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cemiplimab (an immunotherapy drug) plus gemcitabine (a chemotherapy drug)
What this could lead to: If it works, this could offer a new second-line treatment option for people with a specific genetic type of advanced pancreatic cancer.
What could go wrong: This is a small, early-phase trial with only 43 participants, so results may not apply to everyone. The combination may cause side effects like immune reactions or low blood counts, and it may not improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA (MPDAC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Neoplasm Metastasis pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC DUCTAL ADENOCARCINOMA (MPDAC)

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

University of California, San Diego
RECRUITING

La Jolla, California, 92093, United States

Contact Email: •••••@•••••

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.